Clinical Trial

A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 21, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this \[clinical trial\] is to \[evaluate the safety and efficacy of olanzapine-samidorphan tablets\] in \[adults with schizophrenia\]. The main question\[s\] it aims to answer are: * \[question 1\] Olanzapine-samidorphan significantly mitigate weight gain better than olanzapine. * \[question 2\] Olanzapine- samidorphan and olanzapine have similar antipsychotic efficacy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-17.
Trial Details
NCT Number NCT06649214
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Schizophrenia
Enrollment 654 participants
Start Date 2024-11
Primary Completion 2026-04 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2024-10-21